
## Jennifer A Chan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2297610/publications.pdf Version: 2024-02-01



IENNIEED A CHAN

#	Article	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
2	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
3	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature, 2019, 572, 67-73.	27.8	293
4	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
5	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
6	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
7	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nature Genetics, 2014, 46, 39-44.	21.4	167
8	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	10.7	147
9	An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-Oncology, 2012, 14, 184-191.	1.2	145
10	RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway–Dependent Tumors. Cancer Research, 2015, 75, 3623-3635.	0.9	133
11	Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nature Communications, 2020, 11, 4997.	12.8	109
12	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	27.8	94
13	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
14	Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of SurvivalÂin Xenografts and Associated with Glioblastoma Subtypes. Stem Cell Reports, 2015, 5, 1-9.	4.8	72
15	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
16	Proneural bHLH Genes in Development and Disease. Current Topics in Developmental Biology, 2014, 110, 75-127.	2.2	65
17	Heparan Sulfate Proteoglycans Containing a Glypican 5 Core and 2-O-Sulfo-iduronic Acid Function as Sonic Hedgehog Co-receptors to Promote Proliferation. Journal of Biological Chemistry, 2013, 288, 26275-26288.	3.4	64
18	Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. Cancer Cell, 2022, 40, 379-392.e9.	16.8	54

JENNIFER A CHAN

#	Article	IF	CITATIONS
19	The CHD6 chromatin remodeler is an oxidative DNA damage response factor. Nature Communications, 2019, 10, 241.	12.8	45
20	Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19098-19108.	7.1	42
21	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro-Oncology, 2017, 19, 1607-1617.	1.2	39
22	A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors. Nature Medicine, 2017, 23, 1191-1202.	30.7	38
23	Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. Oncotarget, 2014, 5, 7960-7979.	1.8	35
24	Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors. Nature Communications, 2019, 10, 2000.	12.8	34
25	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
26	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells. American Journal of Pathology, 2016, 186, 446-459.	3.8	32
27	Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. Acta Neuropathologica, 2021, 141, 725-754.	7.7	32
28	CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. Cancer Research, 2018, 78, 4745-4759.	0.9	31
29	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Research, 2019, 79, 2111-2123.	0.9	28
30	An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. Nature Communications, 2020, 11, 3627.	12.8	21
31	Copy-scAT: Deconvoluting single-cell chromatin accessibility of genetic subclones in cancer. Science Advances, 2021, 7, eabg6045.	10.3	19
32	A high-throughput alpha particle irradiation system for monitoring DNA damage repair, genome instability and screening in human cell and yeast model systems. Nucleic Acids Research, 2020, 48, e111-e111.	14.5	13
33	Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Clinical Cancer Research, 2021, 27, 1807-1820.	7.0	12
34	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. Cancer Medicine, 2020, 9, 447-459.	2.8	11
35	Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. Communications Biology, 2022, 5, .	4.4	8
36	Unilateral Foot Drop as an Initial Presentation of a Brain Tumor in a Child. Journal of Child Neurology, 2014, 29, 955-958.	1.4	6

#	Article	IF	CITATIONS
37	Population Based Analysis Ependymoma Patients in Alberta from 1975 to 2007. Canadian Journal of Neurological Sciences, 2014, 41, 742-747.	0.5	3
38	TMIC-02CELL AUTONOMOUS AND CELL NON-AUTONOMOUS ROLES OF p75 NEUROTROPHIN RECEPTOR (p75NTR) IN GLIOMA INVASION. Neuro-Oncology, 2015, 17, v214.6-v214.	1.2	0
39	RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG. Neuro-Oncology, 2022, 24, i13-i14.	1.2	0